Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates
January 12 2023 - 4:00PM
Business Wire
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the
Company”), an experienced and innovative biotechnology company
committed to transforming people’s lives by silencing diseases
through precision engineered medicines, today provided the
following SLN360 and SLN124 program updates during a presentation
at the 41st Annual J.P. Morgan Healthcare Conference:
SLN360 for cardiovascular
disease
- The first subjects have been dosed in the SLN360 phase 2 study
in high-risk atherosclerotic cardiovascular disease (“ASCVD”). The
Company plans to complete enrollment in the study in the fourth
quarter of 2023. More information on the trial can be found
here.
- Silence expects data from the ongoing phase 1 multiple dose
study in subjects with high lipoprotein(a) (“Lp(a)”) and stable
ASCVD in the fourth quarter of 2023. In the single dose study
evaluating healthy volunteers with high Lp(a), participants who
received SLN360 (300 mg and 600 mg doses) saw median maximal Lp(a)
reductions of 96% and 98%, respectively.
SLN124 for hematological
diseases
- Sites are open for enrollment in the SLN124 phase 1/2 study in
polycythemia vera (“PV”). The SLN124 PV study is a two-part study
which includes a phase 1 open-label, dose finding study followed by
a phase 2 randomized, double-blind, placebo-controlled parallel arm
study. More information on the trial can be found here.
- Silence expects data from the ongoing phase 1 multiple dose
study of SLN124 in thalassemia patients in the fourth quarter of
2023.
“2023 is poised to be an important and exciting year for
Silence,” said Craig Tooman, President and CEO of Silence. “We were
pleased to initiate dosing in the SLN360 phase 2 ASCVD study and
are very encouraged by the enthusiasm for this program. We also
kicked off the SLN124 PV study and look forward to providing
further updates as we advance the program this year. We remain very
pleased with the prospects for our mRNAi GOLD™ platform.”
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines
by harnessing the body’s natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
need. Silence’s proprietary mRNAi GOLD™ platform can be used to
create siRNAs (short interfering RNAs) that precisely target and
silence disease-associated genes in the liver, which represents a
substantial opportunity. Silence’s wholly owned product candidates
include SLN360 designed to address the high and prevalent unmet
medical need in reducing cardiovascular risk in people born with
high levels of lipoprotein(a) and SLN124 designed to address rare
hematological diseases. Silence also maintains ongoing research and
development collaborations with AstraZeneca, Mallinckrodt
Pharmaceuticals, and Hansoh Pharma, among others. For more
information, please visit
https://www.silence-therapeutics.com/.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and other securities laws, including
with respect to the Company’s clinical and commercial prospects,
regulatory approvals of the Company’s product candidates, potential
partnerships or collaborations or payments under new and existing
collaborations, the initiation or completion of the Company’s
clinical trials and the anticipated timing or outcomes of data
reports from the Company’s clinical trials. These forward-looking
statements are not historical facts but rather are based on the
Company's current assumptions, beliefs, expectations, estimates and
projections about its industry. Words such as 'anticipates,'
'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,'
and similar expressions are intended to identify forward-looking
statements. These statements are not guarantees of future
performance and are subject to known and unknown risks,
uncertainties, and other factors, some of which are beyond the
Company's control, are difficult to predict, and could cause actual
results to differ materially from those expressed or forecasted in
the forward-looking statements, including those risks identified in
the Company’s most recent Admission Document and its Annual Report
on Form 20-F filed with the U.S. Securities and Exchange Commission
(the “SEC”) on March 17, 2022. The Company cautions security
holders and prospective security holders not to place undue
reliance on these forward-looking statements, which reflect the
view of the Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230112005311/en/
Enquiries: Silence Therapeutics plc Gem Hopkins,
Head of IR and Corporate Communications ir@silence-therapeutics.com
Tel: +1 (646) 637-3208
Silence Therapeutics (NASDAQ:SLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Silence Therapeutics (NASDAQ:SLN)
Historical Stock Chart
From Jul 2023 to Jul 2024